Suchergebnisse - "D’Alessio, Antonio"

PubPharm (92)

1

The Hammersmith Score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden

enthalten in: Chemotherapy | 2024

von Korolewicz, J. | Scheiner, B. | Fulgenzi, C. | +22

2

Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma : the PETAL phase Ib study

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Pinato, D. | D'Alessio, A. | Fulgenzi, C. | +21

3

Immunotherapy at all stages of hepatocellular carcinoma

enthalten in: Nature medicine | 2024

von Pinato, D. | Fulgenzi, C. | D'Alessio, A.

4

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

enthalten in: Journal of hepatology | 2024

von Celsa, C. | Cabibbo, G. | Fulgenzi, C. | +69

5

The long and winding road : Adjuvant therapy for early-stage hepatocellular carcinoma

enthalten in: Med (New York, N.Y.) | 2024

von D'Alessio, A. | Rimassa, L.

6

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

enthalten in: JHEP reports : innovation in hepatology | 2024

von Balcar, L. | Scheiner, B. | Fulgenzi, C. | +45

7

Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma : A matching-adjusted indirect comparison

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Agirrezabal, I. | Bouattour, M. | Pinato, D. | +6

8

Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma : a multicentre retrospective study

enthalten in: The Lancet. Oncology | 2023

von Zeng, Q. | Klein, C. | Caruso, S. | +119

9

Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

enthalten in: World journal of gastrointestinal oncology | 2023

von Dharmapuri, S. | Özbek, U. | Jethra, H. | +34

10

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy : A global, observational study

enthalten in: Hepatology communications | 2023

von Joerg, V. | Scheiner, B. | D Alessio, A. | +33

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]